Stockreport

Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF EZHARMIA is the first dual EZH1 and EZH2 inhibitor to receive approval for this indication. The asset previously received the SAKIGAKE designation. Its approval is [Read more]